The second group of viral genetic vaccines tested in ovarian cancer (PANVAC-C + PANVAC-V) involved a poxviral vaccine that is genetically engineered with CEA-MUC1-TRICOM (B7.1, ICAM-1, LFA-3) into fowlpox (PANVAC-C) as a booster and vaccinia (PANVAC-V) as a prime vaccination. The gene discussed is CD80; the disease is ovarian cancer.